A trial looking at ATN-224 and exemestane for breast cancer that is advanced or has come back after treatment in women who are past their menopause

Cancer type:

Breast cancer




Phase 2

This trial was looking at adding ATN-224 to hormone therapy for breast cancer that had spread to another part of the body or had come back after treatment. It was for women who had hormone receptor positive breast cancer.

This trial was supported by Cancer Research UK.

More about this trial

Doctors often use hormone therapy to treat breast cancerExemestane is a type of hormone drug called an aromatase inhibitor Open a glossary item. Aromatase inhibitors are only suitable for women who have been through the menopause Open a glossary item.

ATN-224 is an anti angiogenic drug. This means it stops the cancer forming its own blood vessels. The drug works by binding to copper in the body. Cancer cells need copper to grow new blood vessels. So if there is less copper, the cancer cannot form new blood vessels. This will not directly kill cancer cells, but it may stop or slow down their growth.

In this trial, researchers were looking at exemestane and ATN-224 to see if this combination of drugs helped women with breast cancer.

The aims of the trial were to:

  • see if exemestane and ATN-224 was better than exemestane alone for advanced hormone receptor positive breast cancer
  • learn more about how ATN-224 works
  • find out more about the side effects

Summary of results

This trial was never finished so there are no results available. The researchers were unable to recruit enough patients.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Adrian Harris

Supported by

Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

Other information

This is Cancer Research UK trial number CRUKD/08/043.

We have more information about the work of Professor Adrian Harris.

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think